LINC00152 was used as a competitive endogenous RNA to make oxaliplatin-resistant colon cancer-sponging miR-193a-3p via the LINC00152/miR-193a-3p/erbb4/Akt signaling axis (39). This evidence concerns the gene ERBB4 and malignant colon neoplasm.